Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-UK national security prevents publication of vaccine supply data - junior minister

Fri, 29th Jan 2021 08:23

* UK refuses to publish Astra supply details

* Scotland says it will publish vaccine supply data

* EU warns drug companies over supply delays
(Adds comments from UK's former vaccine head)

By Sarah Young

LONDON, Jan 29 (Reuters) - Britain cannot publish details of
the AstraZeneca COVID-19 vaccine supply contract because
it would jeopardize national security, a junior minister said on
Friday, as the European Union threatened drug companies over
supply delays.

Europe's fight to secure vaccines intensified on Thursday
when the EU warned drug companies that it would use all legal
means or even block exports unless they agreed to deliver shots
as promised.

Scotland will publish COVID-19 detailed vaccine supply data
next week even though the British government has refused to do
so.

British prisons minister Lucy Frazer said the government had
been transparent with data but could not publish supply details
for national security reasons which she repeatedly refused to
specify.

"My understanding is it risks national security," Frazer, a
former barrister, told LBC radio, when asked why the data had
not been published. She refused to say how publication of such
data could hurt national security.

The swiftest mass vaccination drive in history is stoking
tensions across the world as big powers buy up doses in bulk and
poorer nations try to navigate a financial and diplomatic
minefield to collect whatever supplies are left.

Israel is by far the world leader on vaccine rollout per
head of population, followed by the United Arab Emirates, the
United Kingdom, Bahrain and the United States. Behind them are
Italy, Germany, France, China and Russia.

The United Kingdom has secured 367 million doses of the
seven most promising vaccines, including 100 million doses of
the AstraZeneca vaccine which was developed by Oxford
University.

Kate Bingham, the former head of the UK's vaccine taskforce,
said the country had been able to secure supplies by supporting
pharmaceutical companies, setting up clinical trials quickly and
helping firms procure equipment to scale up manufacturing.

She declined to comment on the detail of the contract with
AstraZeneca, but said that the UK had benefited from early work
to be ready to make vaccines.

"That is ultimately the difference as to why we're so far
ahead on manufacturing," Bingham said, adding that she did not
expect the EU to block vaccine exports to the UK.

The EU's contract with AstraZeneca for its COVID-19 vaccine
contains binding orders, EU Commision Head Ursula von der Leyen
said on Friday, demanding a plausible explanation from the
drugmaker for delivery hold-ups.

"I think we'll just go back to publishing the actual supply
figures from next week, so that we all have transparency around
that," Sturgeon told the Scottish parliament on Thursday.
(Reporting by Sarah Young and Alistair Smout; editing by Guy
Faulconbridge and Paul Sandle)

More News
23 Oct 2023 08:45

TOP NEWS: AstraZeneca says Enhertu approved by European Commission

(Alliance News) - AstraZeneca PLC on Monday said its Enhertu treatment has been approved by the European Commission to treat adult lung cancer patients.

Read more
23 Oct 2023 07:46

LONDON BRIEFING: Keller expects higher profit; Upland rejects approach

(Alliance News) - Stocks in London are set to open slightly higher on Monday, as risk sentiment improves after a difficult period for markets last week.

Read more
18 Oct 2023 09:04

AstraZeneca drug Solaris approved in China as NMOSD treatment

(Alliance News) - AstraZeneca PLC on Wednesday announced that eculizumab, whose brand name is Solaris, has been approved in China to treat patients with neuromyelitis optica spectrum disorder

Read more
17 Oct 2023 12:06

LONDON MARKET MIDDAY: European markets uneasy but FTSE 100 outperforms

(Alliance News) - London's FTSE 100 higher was higher around midday, though it was defensive stocks such as utilities and pharmaceuticals which led the charge, suggesting there is still lingering discomfort in markets amid tensions in the Middle East.

Read more
16 Oct 2023 08:34

TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA

(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.

Read more
4 Oct 2023 12:14

IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.

Read more
3 Oct 2023 16:55

LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow

(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
3 Oct 2023 08:36

TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation

(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.

Read more
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.